SeaStar Medical's Quell Immune Growth Faces A Cash And Enrollment Test This Quarter

SeaStar Medical heads into its third-quarter report with an awkward split between its business and its stock. Quell Immune sales have risen for several straight quarters, the hospital customer base keeps widening and management sounded more confident last time than it has in a while. Yet shares have fallen about 36% since the last report, roughly 35 points worse than the S&P 500. The question for the November 11 release, due after the close, is whether commercial progress can outrun a shrinking cash balance and a pivotal trial that is enrolling more slowly than the company wants.

The Street's revenue estimate is more cautious than recent momentum would suggest. Consensus calls for about $500 thousand in revenue, up roughly 173% from a year ago but below the $615 thousand SeaStar booked in the second quarter. That sequential decline matters because management reaffirmed its $2 million full-year target. With $1.1 million already booked through June, the company needs only about $450 thousand a quarter in the back half to get there, so the Street's figure sits comfortably within that goal rather than stretching it. If revenue holds near or above second-quarter levels, it would support management's view that mature sites are moving Quell Immune from last-resort rescue therapy toward earlier, proactive use. A drop toward or below consensus would raise the question of whether the strong second quarter was lumpy rather than the start of a steadier climb. On the bottom line, analysts expect a loss of $0.95 per share, slightly wider than the prior quarter's $0.91 and far wider than the year-ago loss, consistent with rising clinical spending.

Customer count may say more than revenue. SeaStar reached 20 active pediatric hospital customers last quarter, up from 17, and is aiming for 25 by year-end. Further gains would show that adoption is spreading beyond a few heavy users. Gross margin, above 90% for five straight quarters, should stay there. Investors will also want an early read on the new ICD-10 procedure codes that took effect October 1. They will not affect third-quarter sales, but management's comments on whether hospitals see billing getting easier could shape fourth-quarter expectations.

The adult acute kidney injury trial is the larger long-term issue. Enrollment stood at 223 of 339 patients in June, with management acknowledging a pace of roughly 8 to 12 patients a month against a goal of 15 to 20. At the current rate, the update should land somewhere in the high 240s to high 250s. Finishing by year-end would require a much faster pace, so a third-quarter figure well above that range would suggest the newly activated sites are working. A figure at the low end would make the first quarter of 2027 the more realistic completion date and could eventually pressure the late-2027 PMA timeline, which management has so far left unchanged.

Cash is the uncomfortable backdrop. SeaStar ended June with about $7 million, down from $12 million at the start of the year, against a quarterly net loss near $3.7 million. Absent new funding, the September balance could be thin, and any disclosure of financing, its size and its cost to existing holders may move the stock more than the earnings figures themselves. That risk helps explain the sell-off. The stock trades at $2.04, near its post-report low of $1.90 and well below its 200-day moving average of $3.32, and bullish sentiment has slipped to about 63% from nearly 77% a quarter ago.

The commercial story has largely held together. What this report must show is that SeaStar can keep building revenue, add customers and speed up trial enrollment while funding the effort without losing the confidence its operating progress has earned.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.